Chief, General Hematology/Oncology
Assistant Professor, Department of Hematology/Oncology
| Medical Oncology |
For a cancer patient the ideal treatment maximizes quality of life, while minimizing side effects. My philosophy as an oncologist is to guide the patient toward achieving this goal. I strive to ensure that patients and their families have a comprehensive understanding of their disease and available treatment options. In addition, I believe a patient deserves to be treated functionally, emotionally, and socially, as a whole person. By being a part of Fox Chase Cancer Center, I will be working with a team devoted to making this happen.
After completing my fellowship at the Medical University of South Carolina, I am excited to join Fox Chase and the vibrant medical community in Philadelphia. I was immediately impressed by the collegiality of the faculty and staff, as well as the multidisciplinary approach to their care. I am enthusiastic about being involved in the treatment of a variety of solid tumors.
Giri, A., Walia, SS., Gajra, A. Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. Rev Recent Clin Trials. 2016, Jul 24.
Pinto, I., Giri, A., Arshad, U., Gajra, A. New Oral Anticoagulants and Their Reversal. Current Drug Safety. 2015; 10 (3): 208-16.
Aleksiejuk, P., Pawar, L., Giri, A.. Conservative Management of Spontaneous Esophageal Perforation in a Patient with Achalasia. Critical Care Medicine. 2014, Dec; 42(12): A1660.
Giri, A., Goustin, A.S., Wang, S., Al-Katib, A., Mohammad, R.. Surface plasmon resonance study of apoptotic regulators Bcl-2, Bcl-w, Bcl-XL, Mcl-1 and A1 and the small molecule inhibitor (SMI) TW-37: the idea of a temporal window for drug activity. Cancer Research. 2008, May; 68(9S): 3192.
Mohammad, R., Giri, A., Goustin, A. S.. Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer. Recent patents on anti-cancer drug discovery. 2008, Jan; 3(1): 20-30.
Patient comments